The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity

Öfverholm,Anna; Einbeigi,Zakaria; Manouchehrpour,Shokoufeh; Albertsson,Per; Skrtic,Stanko; Enerbäck,Charlotta

doi:10.3892/ol_00000028

The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity

Authors:
- Anna Öfverholm
- Zakaria Einbeigi
- Shokoufeh Manouchehrpour
- Per Albertsson
- Stanko Skrtic
- Charlotta Enerbäck
View Affiliations

Affiliations: Department of Clinical Genetics, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden
Published online on: January 1, 2010 https://doi.org/10.3892/ol_00000028
Pages: 151-154

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paclitaxel is a frequently used anticancer drug with considerable inter-individual variability in terms of drug efficiency and toxicity. The reasons for this variability have not been fully explained. The purpose of this study was to evaluate the possible relationship between paclitaxel-induced neurotoxicity and the distribution of genetic variations with reported functional significance in the ABCB1, CYP2C8 and CYP3A4 genes that are all implicated in taxol metabolism. Women (n=36) experiencing paclitaxel-induced neurotoxicity were included in the study, and the ABCB1 G2677A/T and C3435T as well as CYP2C8*3 and CYP3A4*1b allele frequencies were determined using PCR-RFLP and DNA sequence analysis. We showed that the ABCB1 3435T allele, previously reported as a risk allele for neurotoxicity, did not correlate with the occurrence of neurotoxicity in our patient sample (Chi-square test, p=0.61). Furthermore, we showed that neither the CYP2C8*3 nor CYP3A4*1b alleles, that both lead to diminished enzyme activity, correlated with paclitaxel-induced neurotoxicity. The occurrence and variation in severity of neurotoxicity in our Swedish patient sample could therefore not be explained by the reported functional polymorphisms in the ABCB1, CYP2C8 and CYP3A4 genes.

View Figures

View References

1	Socinski MA: Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin Cancer Res. 10:4210–4214. 2004. View Article : Google Scholar : PubMed/NCBI
2	Fellner S, Bauer B, Miller DS, et al: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 110:1309–1318. 2002. View Article : Google Scholar : PubMed/NCBI
3	Walle UK and Walle T: Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos. 26:343–346. 1998.PubMed/NCBI
4	Huizing MT, Giaccone G, van Warmerdam LJ, et al: Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small cell lung cancer. The European Cancer Centre. J Clin Oncol. 15:317–329. 1997.PubMed/NCBI
5	Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ and Relling MV: Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol. 12:532–538. 1994.PubMed/NCBI
6	Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI and Goldstein JA: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 11:597–607. 2001. View Article : Google Scholar : PubMed/NCBI
7	Harris JW, Rahman A, Kim BR, Guengerich FP and Collins JM: Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54:4026–4035. 1994.PubMed/NCBI
8	Malingré MM, Beijnen JH and Rosing H: Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer. 84:42–47. 2001.PubMed/NCBI
9	Cordon-Cardo C, O’Brien JP, Boccia J, et al: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA. 86:695–698. 1989. View Article : Google Scholar : PubMed/NCBI
10	Schinkel AH, Smit JJ and van Tellingen O: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:491–502. 1994. View Article : Google Scholar : PubMed/NCBI
11	Henningsson A, Marsh S and Loos WJ: Association of CYP2C8, CYP3A4, CYP3A5 and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res. 11:8097–8104. 2005. View Article : Google Scholar : PubMed/NCBI
12	Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A and Mielke S: Association of ABCB1 alleles with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer. 42:2893–2896. 2006. View Article : Google Scholar : PubMed/NCBI
13	Cavalli SA, Hirata MH and Hirata RD: Detection of MboII polymorphism at the 5′ promoter region of CYP3A4. Clin Chem. 47:348–351. 2001.
14	Kim DH, Park JY, Sohn SK, et al: Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer. 118:2195–2201. 2006. View Article : Google Scholar : PubMed/NCBI
15	Spratlin J and Sawyer MB: Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol. 61:222–229. 2007. View Article : Google Scholar
16	Lamba JK, Lin YS, Schuetz EG and Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 54:1271–1294. 2002. View Article : Google Scholar : PubMed/NCBI
17	Gréen H, Söderkvist P, Rosenberg P, Horvath G and Peterson C: Mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res. 12:854–859. 2006.PubMed/NCBI
18	Bahadur N, Leathart JB, Mutch E, et al: CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 64:1579–1589. 2002. View Article : Google Scholar : PubMed/NCBI
19	Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006.
20	Hoffmeyer S, Burk O, von Richter O, et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 97:3473–3478. 2000. View Article : Google Scholar : PubMed/NCBI
21	Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R and Deissler H: Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol. 22:1117–1121. 2003.PubMed/NCBI
22	Siddiqui A, Kerb R, Weale ME, et al: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 348:1442–1448. 2003. View Article : Google Scholar : PubMed/NCBI
23	Cascorbi I, Gerloff T, Johne A, et al: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 69:169–174. 2001. View Article : Google Scholar : PubMed/NCBI
24	Green H: Pharmacogenomics of importance for paclitaxel chemotherapy. Pharmacogenomics. 9:671–674. 2008. View Article : Google Scholar : PubMed/NCBI
25	Keshava C, McCanlies EC and Weston A: CYP3A4 poly-morphisms – potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol. 160:825–841. 2004.
26	Rodríguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L and Ingelman-Sundberg M: Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun. 338:299–305. 2005.PubMed/NCBI